Page 2 - CUAJ Dec. 2022
P. 2

®
      KEYTRUDA
      HAS A NEW INDICATION












      Dear Healthcare Providers,


      We are pleased to inform you that KEYTRUDA  is now indicated for adjuvant treatment,
                                                          ®
      as monotherapy, of adult patients with RCC at intermediate-high or high risk of recurrence
      following nephrectomy, or following nephrectomy and resection of metastatic lesions.










                                         SEE KEYNOTE-564 TRIAL RESULTS



                                           SCAN THE QR CODE TO LEARN MORE











      Consult the Product Monograph at https://www.merck.ca/static/pdf/KEYTRUDA-PM_E.pdf for
      important information relating to contraindications, warnings, precautions, adverse reactions,
      interactions, dosing, and conditions of clinical use. The Product Monograph is also available by
      calling us at 1-800-567-2594.


      Sincerely yours,





      Amy Klug
      Executive Director, Oncology
      Merck Canada Inc.








      ® Merck Sharp & Dohme LLC. Used under license.
      © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.    CA-RCC-00065






 186-2929-[MERCK] RCC NOC Annoucement - PDF V4.indd   1                                                      2022-09-12   12:45 PM
   1   2   3   4   5   6   7